After a gradual ramp-up in the US biosimilars market since the Biologics Price Competition and Innovation Act first created the framework for US biosimilars in 2009, recent years have seen progress accelerate, with several major leaps forward.
Following a boost from a trio of oncology biosimilars – bevacizumab, trastuzumab and rituximab – that were launched by multiple players in 2019 and 2020, last year saw further advances such as the first approved interchangeable and thus substitutable biosimilar, as
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?